Trial Profile
A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
- Indications Prostate cancer
- Focus Pharmacodynamics; Registrational
- 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
- 13 Apr 2012 Results published in the BJU International.
- 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.